Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR12 Rates in Genotype 1 Japanese Patients

99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR[12] with 8 weeks of G/P.

Published
09 January 2017
From
AbbVIe press release
Access to highly effective hepatitis C treatment in Portugal: A Community Perspective

This document presents a case study of community engagement for highly effective hepatitis C treatment, led by the Grupo de Ativistas em Tratamentos. It demonstrates the process of price and reimbursement negotiations in Portugal and lessons learned in advocacy for universal (or as close as possible) access to these and other life-saving drugs.

Published
19 December 2016
From
EATG
Gilead’s Patent Loss to Merck Started With a Broken Friendship

Jury may have been swayed by ‘story of betrayal,’ lawyers say. Gilead will use law, not emotion, to seek to overturn verdict.

Published
19 December 2016
From
Bloomberg
Hepatitis C patients 'go abroad for drugs'

Charities and liver specialists are warning that people with Hepatitis C are buying medications from India, to avoid long waits on the NHS. Radio 4's You & Yours has seen confidential documents, which suggest the cost to the NHS of some medications has dropped by nearly three-quarters, but experts say that NHS England still has not increased the number of patients it will treat.

Published
19 December 2016
From
BBC Radio 4 (audio)
Merck wins $2.54 billion in hepatitis C drug trial against Gilead

Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.

Published
16 December 2016
From
Reuters
First WHO prequalified hepatitis C rapid test opens the door to expanded treatment

WHO has just prequalified its first hepatitis C virus (HCV) rapid diagnostic test, a tool that will aid diagnosis of HCV in low- and middle-income countries and improve access to treatment.

Published
05 December 2016
From
World Health Organization
Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months

Hepatitis C medications approved in March this year have already topped the list of Australia's most expensive drugs, costing the taxpayer $1 billion. The latest figures have outlined 10 most prescribed and most expensive drugs on the Pharmaceutical Benefits Scheme (PBS) in the past year.

Published
05 December 2016
From
ABC Online
New WHO report shows strategic purchasing of medicines can improve access in the European Region

A new WHO report provides insight into how countries in the WHO European Region can improve access and reduce medicine prices through strategic and well-planned procurement processes. The report examines the effect of different public procurement practices on supply security and prices for pharmaceuticals. It also addresses collaboration within and across countries to improve availability of affordable medicines for patients in the Region.

Published
02 December 2016
From
World Health Organization
Hepatitis C Sheds Enough in the Rectum to Transmit Through Anal Sex

Researchers have come up with the first direct evidence that enough hepatitis C virus (HCV) sheds into the rectums of HIV-positive men who have sex with men (MSM) to transmit directly to another man’s penis during anal sex, even when no blood is present.

Published
30 November 2016
From
Poz
DAA treatment restricted for Canadian hepatitis C patients

Patients infected by hepatitis C virus (HCV) in Canada have limited access to direct-acting antiviral (DAA) agents, according to a new study. For example, 85% to 92% of the provinces and territories in Canada restrict access to these medications to persons with moderate fibrosis.

Published
29 November 2016
From
Medical Economics
← First12345...120Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.